Monoclonal Microbial Therapies
as a new class of medicines
Our goal is to leverage the central role of the gut microbiota in the immune system.
Our lead program is a monoclonal microbial drug candidate, using a single strain of the bacteria species Faecalibacterium prausnitzii.
This novel treatment aims at offering a complementary strategy to patients and physicians for the treatment of inflammatory bowel diseases, such as Crohn Disease or Ulcerative Colitis.
Our strain was rationally selected for its superior properties.
Faecalibacterium prausnitzii uniquely combines 4 characteristics:
Natural-occurring bacterial species in the human gut flora of all human beings across all geographies
Most abundant bacterial species in the gut microbiota of healthy subjects
Almost absent in patients with inflammatory bowel diseases
Predictive of good health in patients with inflammatory bowel diseases
We have observed in preclinical studies that orally-delivered pharmaceutical compositions of Faecalibacterium prausnitzii can downregulate immune responses and reduce pain.
We are working to advance our lead candidate into several clinical studies across inflammatory bowel diseases.
In parallel, we are also leveraging our technological advances and know-how to set-up a state-of-the-art platform specialized in the development of new monoclonal microbial candidates in other therapeutic areas.
Exeliom Biosciences Was Founded by a Pioneer Team in the Field of Translational Microbiome Research
Philippe Langella, PhD
RESEARCH DIRECTOR, INRA
Harry Sokol, MD, PhD
PROF. OF GASTROENTEROLOGY, APHP
Patrick Gervais, PhD
PROF. OF PROCESS ENGINEERING,
The complementarity between fundamental research and clinical studies has always been the cornerstone of our success
Nature medicine - 2016.
deficient in Crohn’s disease.
Gut - 2016
BMC Biology - 2015
Gut - 2014
IBD - 2014
PLOS Biology - 2014
67 rue des Godrans, 21000 Dijon
24 rue du Faubourg Saint-Jacques, 75014 Paris (Paris Biotech Santé, Cochin)
For general inquiries contact: